REGENERON PHARMACEUTICALS, INC. Payments for Repurchase of Warrants
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of warrants for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of warrants for the quarter ending 2017-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of warrants for the quarter ending 2017-06-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of warrants for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of warrants for fiscal 2018 was $0.00.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of warrants for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of warrants for fiscal 2016 was $643.40M, a 12.19% increase from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of warrants for fiscal 2015 was $573.49M, a 94.70% increase from fiscal 2014.
| Period end | Payments for Repurchase of Warrants 3 month | Payments for Repurchase of Warrants 12 month |
|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-07 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $0.00 10-K · filed 2019-02-07 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $401.28M derived: sum of 4 quarters · filed 2019-02-07 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $401.28M derived: sum of 4 quarters · filed 2019-02-07 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-04 | $401.28M derived: sum of 4 quarters · filed 2019-02-07 |
| 2016-12-31 | $401.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $643.40M 10-K · filed 2019-02-07 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $292.12M derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $691.07M derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-03-31 | $242.12M 10-Q · filed 2017-05-04 | $691.07M derived: sum of 4 quarters · filed 2018-02-08 |
| 2015-12-31 | $50.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $573.49M 10-K · filed 2018-02-08 |
| 2015-09-30 | $398.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $675.00M derived: sum of 4 quarters · filed 2017-02-09 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $276.04M derived: sum of 4 quarters · filed 2017-02-09 |
| 2015-03-31 | $124.53M 10-Q · filed 2016-05-05 | $419.08M derived: sum of 4 quarters · filed 2017-02-09 |
| 2014-12-31 | $151.51M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $294.55M 10-K · filed 2017-02-09 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $143.04M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-06-30 | $143.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $143.04M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-07 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $0.00 10-K · filed 2016-02-11 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | |
| 2012-12-31 | $0.00 10-K · filed 2015-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |